Abstract:Background: The participation of major histocompatibility complex (MHC) in antigen presentation shapes both the breadth and magnitude of specific T cell response. Dendritic cells (DCs) activated with nucleic acid or protein that encodes/incorporates multiple antigenic epitopes elicit MHC class I- and II- biased immunity, respectively. Studies demonstrate that an elevated MHC class I-directed CD8+ cytotoxicity T lymphocyte (CTL) response is able to provide survival benefits to patient with malignant tumor. However, a fully effective cancer therapy must elicit a diverse repertoire of both CD4+ and CD8+ T cell responses, raising demands on a multifaceted activation of the MHC system. Current therapeutic strategies usually lack an orchestrated mobilization of the MHC class I and II responses. Vaccines with little synergistic effect or unmanageable elicitation of the CD4+ and CD8+ T cell immunity usually fail to induce a potent and durable anti-tumor protection. Methods: Here, cationic nanoemulsions (CNEs) complexed with full-length tumor model antigen ovalbumin (OVA) in the form of mRNA or protein were constructed and used as two antigenic platforms to prepare DCs vaccines with tailored MHC participation (i.e., mRNA-DCs and protein-DCs). In exploring a vaccine regimen with optimal tumor suppressing effect, the mixing ratio of mRNA-DCs and protein-DCs was manipulated. Results: Therapeutic DCs vaccines involving both antigenic platforms induced better anti-tumor immunity in murine E.G7-OVA lymphoma model and B16-OVA melanoma model, which can be further augmented upon a meticulous reallocation of the MHC class I and II responses. Conclusion: This work indicated that a simultaneous and coordinated mobilization of the MHC-restricted immunity might potentiate cancer therapy.

MHC Class II Restricted Neoepitope Vaccine: Promising Strategy for Immunotherapy.

MHC class II restricted neoantigen: A promising target in tumor immunotherapy

Cancer neoantigens as potential targets for immunotherapy

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy

Recent advances of neoantigen in tumor therapy

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy

Neoantigens: promising targets for cancer therapy

Neoantigen: A New Breakthrough in Tumor Immunotherapy

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens

Neoantigens and NK Cells: “Trick or Treat” the Cancers?

Personalized Neoantigen Vaccination with Synthetic Long Peptides: Recent Advances and Future Perspectives

Level of expression of MHCI-presented neoepitopes influences tumor rejection by neoantigen-specific CD8+ T cells

Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines

Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma

Cancer Vaccines: Recent Insights and Future Directions

Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy

Nanovaccine Based on a Biepitope Antigen to Potentiate the Immunogenicity of a Neoantigen

Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens

Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines

Personalized Cancer Neoantigen Vaccines Come of Age

Immunization with short peptide particles reveals a functional CD8 + T-cell neoepitope in a murine renal carcinoma model